Results 161 to 170 of about 173,603 (282)
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk +5 more
wiley +1 more source
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Cardiovascular Prevention in Children, Adolescents, and Young Adults. A Call-to-Action of the Italian Societies of Pediatrics (SIP), Hypertension (SIIA), Study of Atherosclerosis (SISA), and Cardiovascular Prevention (SIPREC). [PDF]
Genovesi S +12 more
europepmc +1 more source
‘Explaining Failure: the Highs and Lows of Sardinian Nationalism’ [PDF]
Hepburn, Eve
core +1 more source
This systematic literature review aimed to identify and characterize existing interventions designed to empower citizens to spontaneously report adverse drug reactions (ADRs) and to determine which interventions have been shown to be the most effective internationally. The research question was structured using the PICO framework.
Margarida Perdigão +3 more
wiley +1 more source
End of Life in Italy: Ethical and Legal Perspectives. [PDF]
Ciliberti R +3 more
europepmc +1 more source
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić +7 more
wiley +1 more source

